39496-87-2

Upstream product

• 766-51-8 2-Chloroanisole 
• 107776-24-9 4-(3-chloro-4-methoxy-phenyl)-4-oxo-butyric acid ethyl ester 
• 108-30-5 succinic acid anhydride 

Downstream Products

• 854432-88-5 4-(3-chloro-4-methoxy-phenyl)-butyric acid 
• 100119-67-3 4-(3-chloro-4-methoxy-phenyl)-4-oxo-butyric acid methyl ester 
• 56872-21-0 3-(3-chloro-4-hydroxybenzoyl)propionic acid 
• 1370702-20-7 C₁₇H₁₅ClN₂O₂ 
• 1344096-50-9 C₁₇H₁₃ClN₂O₂ 
• 39496-69-0 6-(3-chloro-4-methoxyphenyl)-4,5-dihydropyridazin-3(2H)-one 
• 1026551-26-7 4-[(6-Chloro-7-isopropoxy-1-oxo-1,2,3,4-tetrahydro-naphthalen-2-yl)-hydroxy-methyl]-benzoic acid methyl ester 
• 1026947-44-3 4-(3-Chloro-4-methoxy-phenyl)-butyryl chloride 
• 169300-49-6 6-chloro-7-methoxy-3,4-dihydro-2H-naphthalen-1-one 
• 74362-74-6 4-(3-Chloro-4-isopropoxy-phenyl)-4-oxo-butyric acid 
• 56872-23-2 methyl 3-(3-chloro-4-hydroxybenzoyl)propionate 

Relevant academic research and scientific papers

N-(2-(SUBSTITUTED-NAPHTH-1-YL)ETHYL) SUBSTITUTED AMIDE COMPOUND, PREPARATION AND USES THEREOF

The present disclosure relates to an N-(substituted naphthyl-ethyl) substituted amide compound and uses thereof serving as a melatonin receptor agonist and 5-HT2C receptor antagonist, and specifically relates to the compound of formula (I) or a

A novel type of retinoic acid receptor antagonist: Synthesis and structure-activity relationships of heterocyclic ring-containing benzoic acid derivatives

A new series of heterocyclic ring-containing benzoic acids was prepared, and the binding affinity and antagonism of its members against all-trans- retinoic acid were evaluated by in vitro assay systems using human promyelocytic leukemia (HL-60) cells. Structure-activity relationships indicated that both an N-substituted pyrrole or pyrazole (1-position) and a hydrophobic region, with these linked by a ring system, were indispensable for effective antagonism. Among the compounds evaluated, optimal antagonism was exhibited by 4-[4,5,7,8,9,10-hexahydro-7,7,10,-10-tetramethyl-1-(3- pyridylmethyl)anthra[1,2-b]pyrrol-3-yl]benzoic acid (31), 4-[4,5,7,8,9,10- hexahydro-7,7,10,10-tetramethyl-1-(3-pyridylmethyl)-5-thiaanthra[1,2- b]pyrrol-3-yl]benzoic acid (40), and 4-[4,5,7,8,9,10-hexahydro-7,7,10,10- tetramethyl-1-(3-pyridylmethyl)anthra[2,1-d]pyrazol-3-yl]benzoic acid (55), all of which possess a 3-pyridylmethyl group at the five-membered ring nitrogen atom.

ON THE QUANTITATIVE RELATIONS BETWEEN STRUCTURE AND ANTIAGGREGATION ACTIVITY OF ω-ARYL-ω-OXOALKANOIC ACIDS

A series of ω-aryl-ω-oxoalkanoic acids, I-IV, has been prepared and investigated for dissociation constants in 80percent methylcellosolve, retention characteristics in thin-layer partition chromatography and partition coefficients P in the system octanol-water.Also evaluated were their anti-inflammatory efficacy and inhibitory effect on the platelet aggregation induced by collagen.Analysing the relations between structure and antiaggregation effect, we obtained a non-linear, quadratic dependence of this effect on lipophilicity, the optimum being at log P = 3.The antiaggregation effect increased with shortening the chain between the carbonyl and the carboxyl, and with increasing acidity.It was also diminished by the presence of a methyl group on the interlinking chain.To assess the role of lipophilicity we used the RM values of partition chromatography.The relation between anti-inflammatory efficacy and structure was assessed only qualitatively.In this aspect, too, the nature of the chain between the carbonyl and carboxyl proved to have a marked influence.The anti-inflammatory activity proved considerably enhanced by the presence of another aromatic ring in ω-oxoalkanoic acids derived from biphenyl.